Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, has launched its enhanced bioassay platform, EpiScreen 2.0, a suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.   The next-generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early-phase development.   T...